U.S. Court of Appeal cites application for suspension of import ban
An emergency motion to interim stay filed by Daewoong Pharmaceutical on February 15 (local time) with the US Court of Appeals for the Federal Circuit (CAFC). Said that it was cited. As a result, sales of the botulinum toxin drug Nabota (Juveau, a US export name), which the U.S. International Trade Commission (ITC) ordered to ban imports for 21 months last December, can resume without a gap. Daewoong Pharmaceutical said that the import ban was issued in December and came into effect, but it has been selling bulletins after paying a deposit.
According to Daewoong, the temporary injunction was quickly quoted three days after the application for temporary injunction on the 12th. The bond conditions are the same as before, and, like the ITC deposit, the payee will be determined by the appeal court or the final decision of the Supreme Court. In other words, if Evolus, the exclusive distributor of the bulletin, wins the appeals trial or the final decision of the Supreme Court, the entire deposit will be returned. The emergency provisional injunction is valid until the appellate court’s decision to cite this provisional injunction. did.
An official from Daewoong Pharmaceutical welcomed, “The CAFC’s rapid decision allows Ebolus to continue its business even during the appeal period.”
Reporter Kim Deok-seong of the Legal Times ([email protected])
Copyright © Legal Times Unauthorized reproduction and redistribution prohibited